Fusao Ikeda

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 438 citations

Fibrosis, Hepatology, Liver Physiology +9

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

Masashi Mizokami, Osamu Yokosuka, Tetsuo Takehara et al. · The Lancet Infectious Diseases · 2015 · 361 citations

Hepatology, Hepatitis C, Viral Hepatitis +8

Suppression of Hcv–Specific T Cells Without Differential Hierarchy Demonstrated Ex Vivo In Persistent Hcv Infection

Kazushi Sugimoto, Fusao Ikeda, Jason Stadanlick et al. · Hepatology · 2003 · 350 citations

Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 <scp>HCV</scp> infection: an open‐label, phase 3 trial

Masao Omata, Shuhei Nishiguchi, Yoshiyuki Ueno et al. · Journal of Viral Hepatitis · 2014 · 201 citations · Full text

Japanese Patients, Hcv Infection, Hepatology +13

Discordant Role of CD4 T-Cell Response Relative to Neutralizing Antibody and CD8 T-Cell Responses in Acute Hepatitis C

David E. Kaplan, Kazushi Sugimoto, Kimberly P. Newton et al. · Gastroenterology · 2006 · 155 citations

Neutralizing Antibody, Acute Hepatitis C, Autoimmune Disease +10